𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting — the Nordic experience

✍ Scribed by Bengt Sorbe; Håkan Andersson; Margareta Schmidt; Martin Söderberg; Thomas Högberg; Lars Wernstedt; Eva Tiensuu Janson; Bengt Ehrnström; Mogens Kjaer; Hanne Havsteen; Maria Overgaard; Erik Sandberg; Martti Flander; Mirja Heikkinen; Väinämö Nikkanen

Publisher
Springer-Verlag
Year
1994
Tongue
English
Weight
911 KB
Volume
2
Category
Article
ISSN
0941-4355

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tropisetron in the prevention of nausea
Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy
✍ Benoit, Yves ;Hulstaert, Frank ;Vermylen, Christiane ;Sariban, Eric ;Hoyoux, Cla 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract Tropisetron (Navoban®, Sandoz Pharma Ltd., Basel, Switzerland), a selective antagonist of the serotonin receptor (5‐HT3) dosed once‐daily at 0.2 mg/kg (with a maximum of 5 mg daily), was evaluated in the prevention of chemotherapy‐induced nausea and vomiting in 131 children with a media

Letter to the editor: Tropisetron in the
Letter to the editor: Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy
✍ Berberoglu, Semha 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 10 KB 👁 3 views

Tropisetron in the Prevention of Nausea and Vomiting in 131 Children Receiving Cytotoxic Chemotherapy I have read with interest the report by Benoit et al. [1] were two infants. I agree with the authors that the efficacy and safety data was similar to those reported for older concerning the efficacy

Ondasetron versus granisetron in the pre
Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trial
✍ Vittorio Gebbia; Giuseppe Cannata; Antonio Testa; Giuseppina Gurto; Roberto Vale 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 731 KB

Background. A single-institution, prospective, randomized open trial was performed to compare ondansetron and granisetron in the prevention of chemotherapyrelated nausea and vomiting. The effect of antemetic drugs was analyzed indipendently for patients treated with highly emetogenic chemotherapy (S

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to